Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia.

MLA

Boutoleau-Bretonnière C, et al. “Value of Neuropsychological Testing, Imaging, and CSF Biomarkers for the Differential Diagnosis and Prognosis of Clinically Ambiguous Dementia.” Journal of Alzheimer’s Disease, vol. 28, no. 1, Jan. 2012, pp. 323–36. EBSCOhost, https://doi.org/10.3233/JAD-2011-110761.

APA

Boutoleau-Bretonnière C, Lebouvier T, Delaroche O, Lamy E, Evrard C, Charriau T, Bretonnière C, Damier P, Derkinderen P, Vercelletto M, Boutoleau-Bretonnière, C., Lebouvier, T., Delaroche, O., Lamy, E., Evrard, C., Charriau, T., Bretonnière, C., Damier, P., Derkinderen, P., & Vercelletto, M. (2012). Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia. Journal of Alzheimer’s Disease, 28(1), 323–336. https://doi.org/10.3233/JAD-2011-110761

Chicago

Boutoleau-Bretonnière C, Lebouvier T, Delaroche O, Lamy E, Evrard C, Charriau T, Bretonnière C, et al. 2012. “Value of Neuropsychological Testing, Imaging, and CSF Biomarkers for the Differential Diagnosis and Prognosis of Clinically Ambiguous Dementia.” Journal of Alzheimer’s Disease 28 (1): 323–36. doi:10.3233/JAD-2011-110761.